Article

The time has come for lung cancer screening

Author(s):

To paraphrase Winston Churchill, "This is not the end, but it is certainly the beginning of the end." I firmly believe that 2012 could be remembered as the year that changes the course of lung cancer given the efforts under way by patient advocates and medical leaders to bring responsible, safe and effective early detection to the at risk public.In addition, by bringing best practices in a continuum of care linking prevention, early detection and treatment, we will stimulate more research and new approaches to identifying those at risk, preventing and treating lung cancer, more effective smoking cessation protocols and a better understanding of other causes of lung cancer.Last February Lung Cancer Alliance has launched first of a kind "The National Framework for Excellence in Lung Cancer Screening and Continuum of Care," guidance for both consumers at risk as well as sites offering care. The National Framework presents in three parts. First, it advises the public on their rights--starting with the right to know if someone is at risk for lung cancer. Risk factors include smoking history; family history of lung cancer; environmental exposures to radon, secondhand smoke, asbestos and other known carcinogens; exposure to battlefield fuels; history of other lung diseases. If someone has one or more of these risk factors, they need to talk to their doctor about screening with a low dose CT scan. Second, the National Framework lays out guiding principles of screening and the continuum of care for screening sites. LCA contacts each one to ascertain that they are a multi-disciplinary team and that they follow a coordinated continuum of care for screening, diagnosis and disease management that complies with comprehensive standards based on best published practices. Once identified, LCA lists these sites and alerts the public on www.screenforlungcancer.org. Third, the National Framework establishes the Lung Cancer Screening Excellence Forum. This Forum will be comprised of leading medical and health professionals as well as industry and insurance representatives. The Forum is a mechanism for the discussion of how best to collect data on outcomes, analyze the data and build feedback improvements into the system of care. If tissue, blood, breath and urine samples are collected during the screening process, biomedical research into all types of lung cancer, precancerous conditions and improved treatments can be accelerated and better coordinated. The time has come for lung cancer screening and its continuum of care to be embraced. It is a matter of life or death. If we move swiftly and responsibly we can reduce lung cancer mortality by half by 2020. Laurie Fenton Ambrose

President & CEO

Lung Cancer Alliance

Lungcanceralliance.org

Related Videos
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Related Content